Feb 6 (Reuters) - Eli Lilly and Co LLY.N:
LILLY EXEC SAYS UPTAKE OF SINGLE-USE ZEPBOUND VIALS INCREASED IN Q4 THROUGH DIRECT TO CONSUMER WEBSITE SALES - CONF CALL
LILLY EXEC SAYS U.S. ZEPBOUND PERFORMANCE IS GOING VERY WELL
LILLY EXEC SAYS IN Q4 ZEPBOUND BECAME THE MARKET LEADER IN THE ANTI-OBESITY MARKET AS MEASURED BY NEW PRESCRIPTIONS
LILLY EXEC SAYS U.S. PRESCRIPTIONS OF ALZHEIMER'S DRUG KISUNLA STEADILY INCREASING SINCE LAUNCH
LILLY EXEC SAYS CO PLANS TO START SEVERAL TRIALS ASSESSING INCRETINS IN AREAS SUCH AS BRAIN HEALTH, SUBSTANCE USE DISORDERS, PAIN, OTHERS
Further company coverage: LLY.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.